Cargando…

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

OBJETIVE: To evaluate the effect of ribociclib versus endocrine therapy on productivity losses due to advanced breast cancer. METHODS: Productivity data from the MONALEESA-7 trial, obtained from the results of the application of the Work Productivity and Activity Impairment (WPAI) questionnaire on p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Faculdade de Saúde Pública da Universidade de São Paulo 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749720/ https://www.ncbi.nlm.nih.gov/pubmed/36515302 http://dx.doi.org/10.11606/s1518-8787.2022056004160

Ejemplares similares

The impact of COVID-19 pandemic on colorectal cancer patients at an NHS Foundation Trust hospital-A retrospective cohort study
por: Lesi, Omotara Kafayat, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2022)

Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer
por: Tripathy, Debu, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Impact of COVID-19 on Colorectal Cancer Patients at Basildon and Southend University Hospitals
por: Abdalla Al-Zawi, Abdalla Saad, et al.
Publicado: (2022)

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
por: Loke, Lydia, et al.
Publicado: (2020)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
por: Fasching, Peter A., et al.
Publicado: (2020)

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
por: Verma, Sunil, et al.
Publicado: (2018)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
por: Harbeck, Nadia, et al.
Publicado: (2020)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Breast Cancer Mortality in Young Women in Brazil
por: Silva, Juliana Dalcin Donini E., et al.
Publicado: (2021)

The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer
por: Iida, Masafumi, et al.
Publicado: (2019)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Ribociclib in newly diagnosed hepatitis B infection: A case report
por: Di Costanzo, Fabrizio, et al.
Publicado: (2023)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
por: Al-Ziftawi, Nour Hisham, et al.
Publicado: (2022)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
por: Alotaibi, Wedad H., et al.
Publicado: (2022)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib
por: Menteşoğlu, Dilek
Publicado: (2023)

Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review
por: Badran, Omar, et al.
Publicado: (2023)

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation
por: Jhan, Jyun-Yan, et al.
Publicado: (2023)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9bjnjt0nheu6mb44tjujjkfqj